KRAS and non-small cell lung carcinoma: Among KRAS mutations in BTC, the G12C mutation is rare (~ 1–2%), but KRAS G12C inhibitors, such as adagrasib and sotorasib, have already been approved by the FDA for the treatment of non-small cell lung cancer (NSCLC) and are now being investigated in clinical trials for the treatment of BTC (Table 2).